Literature DB >> 1769735

[Effect of L-carnitine supplementation on lipid metabolism of renal failure, dialysis-dependent children and adolescents].

H Böhles1, D Michalk, E von Wendt-Göknur.   

Abstract

In six renally insufficient children and adolescents (age: 8-21 years) on hemodialysis the effect of L-carnitine supplementation at two dose levels (10 mg/kg/d vs. 100 mg/kg/d) on parameters of lipid metabolism was investigated. L-Carnitine substitution was carried out over four weeks per dose level. Under this regime a significant increase of the serum carnitine concentration occurred together with a decrease in the AC/FC-ratio (x: 1.59 to x:0.83). During the same period a significant decrease in serum triglyceride levels as well as an increase in serum HDL-cholesterol were observed. An inverse correlation (r = -0.63; p less than 0.0008) was found between HDL-cholesterol and the AC/FC-ratio. L-carnitine supplementation and its increasing effect on HDL-cholesterol in patients with renal insufficiency may be considered as antiatherogenic.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1769735

Source DB:  PubMed          Journal:  Infusionstherapie        ISSN: 1011-6966


  3 in total

Review 1.  The use of levo-carnitine in children with renal disease: a review and a call for future studies.

Authors:  Brook Belay; Nora Esteban-Cruciani; Christine A Walsh; Frederick J Kaskel
Journal:  Pediatr Nephrol       Date:  2005-12-23       Impact factor: 3.714

2.  Effects of combined treatment with simvastatin and L-carnitine on triglyceride levels in diabetic patients with hyperlipidaemia.

Authors:  Francesco Brescia; Elisabetta Balestra; Maria Grazia Iasella; Aurelia Bellomo Damato
Journal:  Clin Drug Investig       Date:  2002-11       Impact factor: 2.859

3.  Carnitine supplementation improves apolipoprotein B levels in pediatric peritoneal dialysis patients.

Authors:  Celalettin Koşan; Lale Sever; Nil Arisoy; Salim Calişkan; Ozgür Kasapçopur
Journal:  Pediatr Nephrol       Date:  2003-10-02       Impact factor: 3.714

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.